JADPRO Live 2017 Educational Activities

These educational activities are based on presentations from JADPRO Live at APSHO 2017. Access the full-length video presentation, the slide deck, transcript, and the entire lecture as a podcast. Click on any of the video presentations below to get started!

All  |  AML  |  BRCA  |  Immunotherapy  |  PARP  |  CML  |  MDS  |  MPN  |  Colon Cancer  |  Colorectal Cancer  |  Lynch Syndrome  |  mCRC  |  MSI-H  |  Rectal Cancer  |  CAR T-Cell Therapy  |  irAEs  |  Side Effect Management  |  ALK Positive NSCLC  |  EGFR Resistance  |  Lymphomas and Leukemias  |  Bladder Cancer  |  Urothelial Carcinoma  |  GIST  |  Leiomyosarcoma  |  Soft Tissue Sarcomas  |  Surgery  |  Drug Development  |  MRD  |  Multiple Myeloma  |  Oral Therapies  |  Risk Stratification  |  Adjuvant Treatment  |  Breast Cancer  |  Diarrhea  |  HER2 Positive Breast Cancer
Advances in the Management of Patients with Urothelial Carcinomas of the Bladder

This activity is supported by an independent educational grant from Merck Sharp & Dohme Corp.

Advances in the Management of Patients with Urothelial Carcinomas of the Bladder

Get an update on the state of chemotherapy and immunotherapy for the treatment of urothelial carcinomas of the bladder. Learn how these therapies combat the various types of urothelial carcinomas and how to identify their most common side effects, including immune-related adverse effects from immunotherapy.

Posted: January 22, 2018 / Expires: January 22, 2019

This certified activity has expired but you may watch the video without claiming credit.

Watch Video Without Claiming Credit


Copyright © 2010-2019 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.